Karyopharm Therapeutics Inc. (KPTI) Financial Statements (2024 and earlier)

Company Profile

Business Address 85 WELLS AVENUE
NEWTON, MA 02459
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments236,765260,384277,967148,381170,846205,311
Cash and cash equivalents80,89484,062135,18871,35182,248153,256
Short-term investments155,871176,322142,77977,03088,59852,055
Restricted cash and investments5678461,0641,0801,1461,014
Receivables32,28035,20047,08627,44623,47924,992
Inventory, net of allowances, customer advances and progress billings3,6723,8274,2244,2493,4703,874
Inventory3,6723,8274,2244,2493,4703,874
Prepaid expense    10,05311,42812,207
Other current assets    31,46832,07829,135
Other undisclosed current assets18,09718,28419,821   
Total current assets:291,381318,541350,162222,677242,447276,533
Noncurrent Assets
Operating lease, right-of-use asset5,2965,7766,2386,6817,1077,518
Property, plant and equipment7668491,1391,2521,3951,544
Restricted cash and investments387634633626631636
Other undisclosed noncurrent assets    4,8987,802
Total noncurrent assets:6,4497,2598,0108,55914,03117,500
TOTAL ASSETS:297,830325,800358,172231,236256,478294,033
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities54,09556,07761,18856,52958,06161,811
Accounts payable2,2879,0452,7738131,6943,440
Accrued liabilities51,80847,03258,41555,71656,36758,371
Other liabilities1,7492,5011,8482,4621,8652,063
Other undisclosed current liabilities3,0842,9772,8722,7702,6152,463
Total current liabilities:58,92861,55565,90861,76162,54166,337
Noncurrent Liabilities
Long-term debt and lease obligation170,497170,306170,105176,757177,277177,777
Long-term debt, excluding current maturities170,497170,306170,105169,894169,693169,491
Liabilities, other than long-term debt6,9356,3956,097   
Other liabilities2,4351,085    
Operating lease, liability4,5005,3106,0976,8637,5848,286
Other undisclosed noncurrent liabilities132,718132,718132,718126,135125,414124,712
Total noncurrent liabilities:310,150309,419308,920309,755310,275310,775
Total liabilities:369,078370,974374,828371,516372,816377,112
Equity
Equity, attributable to parent(71,248)(45,174)(16,656)(140,280)(116,338)(83,079)
Common stock121212888
Additional paid in capital1,340,2181,333,2981,327,9091,165,8971,153,3011,136,873
Accumulated other comprehensive income (loss)(783)(419)(638)(752)(538)87
Accumulated deficit(1,410,695)(1,378,065)(1,343,939)(1,305,433)(1,269,109)(1,220,047)
Total equity:(71,248)(45,174)(16,656)(140,280)(116,338)(83,079)
TOTAL LIABILITIES AND EQUITY:297,830325,800358,172231,236256,478294,033

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues37,57938,69833,58036,14539,67947,670
Gross profit:37,57938,69833,58036,14539,67947,670
Operating expenses(67,152)(69,597)(67,449)(66,984)(82,587)(82,256)
Operating loss:(29,573)(30,899)(33,869)(30,839)(42,908)(34,586)
Nonoperating expense(2,930)(3,173)(4,564)(5,440)(6,033)(6,683)
Investment income, nonoperating2,8242,8491,33465829374
Interest and debt expense(5,784)(5,758)(5,885)(6,114)(6,313)(6,684)
Loss from continuing operations before equity method investments, income taxes:(38,287)(39,830)(44,318)(42,393)(55,254)(47,953)
Other undisclosed income from continuing operations before income taxes5,7845,7585,8856,1146,3136,684
Loss from continuing operations before income taxes:(32,503)(34,072)(38,433)(36,279)(48,941)(41,269)
Income tax expense(127)(54)(73)(45)(121)(130)
Loss from continuing operations:(32,630)(34,126)(38,506)(36,324)(49,062)(41,399)
Loss before gain (loss) on sale of properties:(36,324)(49,062)(41,399)
Net loss available to common stockholders, diluted:(32,630)(34,126)(38,506)(36,324)(49,062)(41,399)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(32,630)(34,126)(38,506)(36,324)(49,062)(41,399)
Comprehensive loss:(32,630)(34,126)(38,506)(36,324)(49,062)(41,399)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(364)219114(214)(625)(104)
Comprehensive loss, net of tax, attributable to parent:(32,994)(33,907)(38,392)(36,538)(49,687)(41,503)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: